About Stramsen Biotech
Stramsen Biotech is a Healthcare company based in Houston (United States) founded in 2020. Drugs for cancer, wound, and infectious disease treatments are developed. Stramsen Biotech has raised $10 million across 1 funding round. Stramsen Biotech offers products and services including SBX 1052, SBX1968, SBX 2021, SBX 2022, and SBX 2023. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Stramsen Biotechnology Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Stramsen Biotech was founded in 2020 and is based in Houston, United States. Focus is placed on the biotechnology sector, where pharmaceutical drugs are developed for cancer treatment, wound healing, and infectious diseases. Operations involve research and development activities aimed at therapeutic solutions. The companys domain, stramsenbiotech.com, supports its online presence in the healthcare industry.
- Headquarters Houston, United States
- SectorsHealthcare
- Website stramsenbiotech.com
- Social X Facebook
- Legal Name Stramsen Biotechnology Inc.
- Total Equity Funding$10M (USD)
in 1 rounds
- Latest Funding Round$10M (USD), Series A
Oct 2023
Products & Services of Stramsen Biotech
Stramsen Biotech offers a comprehensive portfolio of products and services, including SBX 1052, SBX1968, SBX 2021, SBX 2022, and SBX 2023.
Controls enlargement of prostate glands through plant-based methods
Prevents proliferation and metastasis of prostate cancer
Controls proliferation and metastasis of various cancer cells
Prevents proliferation and metastasis of blood cancer
Treats peripheral neuropathic disorders effectively
Manages various forms of cardiovascular diseases
Promotes wound healing with antibacterial properties
Controls HIV and enhances immunity
Controls diabetes symptoms
Treats kidney infections and dissolves gallstones
Relieves bone and joint pains, improves lubrication
Funding Insights of Stramsen Biotech
Stramsen Biotech has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Series A — $10M
- First Round $10M
(Oct 2023)
All 1 funding rounds of Stramsen Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $10M | Series A | – | – | – |
Timeline of Stramsen Biotech
2 dated milestones of Stramsen Biotech across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Stramsen Biotech is founded.
- Funding First funding round of $10.0M.
Competitors of Stramsen Biotech
Stramsen Biotech has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Stramsen Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Stramsen Biotech
Websites that share an audience with Stramsen Biotech (stramsenbiotech.com).
Websites whose visitors overlap most with Stramsen Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellingbiosciences.com | 100% | View details | |||
| xbiotech.com | 96% | 3.9K | #4,929,272 | View details | |
| synergybioscience.com | 89% | 1.4K | #9,904,970 | View details | |
| phoenixbiotechnology.com | 85% | View details | |||
| vgxii.com | 84% | 2.9K | #6,447,856 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Stramsen Biotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Stramsen Biotech (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stramsen Biotech
Complete news archive for Stramsen Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stramsen Biotech
Stramsen Biotech was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Stramsen Biotech is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Stramsen Biotech is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series A of $10M, raised on Oct 2023.
Stramsen Biotech was founded in 2020 and is based in Houston, United States. Focus is placed on the biotechnology sector, where pharmaceutical drugs are developed for cancer treatment, wound healing, and infectious diseases. Operations involve research and development activities aimed at therapeutic solutions. The companys domain, stramsenbiotech.com, supports its online presence in the healthcare industry.
Stramsen Biotech offers SBX 1052, SBX1968, SBX 2021, SBX 2022, and 6 more products and services.
Stramsen Biotech operates through Stramsen Biotechnology Inc..